Online citations, reference lists, and bibliographies.
← Back to Search

Suppression, Subversion And Escape: The Role Of Regulatory T Cells In Cancer Progression

K. Oleinika, R. Nibbs, G. Graham, A. R. Fraser
Published 2013 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Regulatory T cells (Tregs) are crucial in mediating immune homeostasis and promoting the establishment and maintenance of peripheral tolerance. However, in the context of cancer their role is more complex, and they are thought to contribute to the progress of many tumours. As cancer cells express both self‐ and tumour‐associated antigens, Tregs are key to dampening effector cell responses, and therefore represent one of the main obstacles to effective anti‐tumour responses. Suppression mechanisms employed by Tregs are thought to contribute significantly to the failure of current therapies that rely on induction or potentiation of anti‐tumour responses. This review will focus on the current evidence supporting the central role of Tregs in establishing tumour‐specific tolerance and promoting cancer escape. We outline the mechanisms underlying their suppressive function and discuss the potential routes of Tregs accumulation within the tumour, including enhanced recruitment, in‐situ or local proliferation, and de‐novo differentiation. In addition, we review some of the cancer treatment strategies that act, at least in part, to eliminate or interfere with the function of Tregs. The role of Tregs is being recognized increasingly in cancer, and controlling the function of these suppressive cells in the tumour microenvironment without compromising peripheral tolerance represents a significant challenge for cancer therapies.
This paper references
10.4049/jimmunol.0904028
Expression of Helios, an Ikaros Transcription Factor Family Member, Differentiates Thymic-Derived from Peripherally Induced Foxp3+ T Regulatory Cells
A. Thornton (2010)
Administration of a CD 25 - directed immunotoxin , LMB - 2 , to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
DJ Powell (2007)
10.1007/s11523-012-0208-y
Targeting regulatory T cells
C. Ménétrier-Caux (2012)
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3[+] regulatory T cells in gastric cancer
水上 佳樹 (2008)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1586/era.11.102
Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas
S. Pellegatta (2011)
10.1200/JCO.2006.09.4565
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
Q. Gao (2007)
10.1111/j.1600-065X.2011.01007.x
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
S. Quezada (2011)
10.1084/jem.20030152
Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3
W. Chen (2003)
Increased Intratumoral FOXP 3 - positive regulatory immune cells during interleukin - 2 treatment in metastatic renal cell carcinoma
HK Jensen (2009)
10.1038/ni.1774
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo
X. Zhou (2009)
10.1097/00002371-199607000-00006
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
G. Maclean (1996)
Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice.
S. Yoshida (1979)
T cell lineage in vivo
MA Gavin (2010)
Human leukocyte antigen class I , MHC class I chain - related molecule A , and CD 8 ( + ) / regulatory T - cell ratio : which variable determines survival of cervical cancer patients ?
ES Jordanova (2008)
Specific recruitment of CC chem
T Ishida (2000)
10.1073/pnas.0811556106
Heterogeneity of natural Foxp3+ T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity
N. Komatsu (2009)
Tumor cells convert imma
F Ghiringhelli (2009)
10.1016/j.immuni.2009.03.019
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.
M. Miyara (2009)
Conversion of peripheral CD 4 ( + ) CD 25 ( – ) naive T cells to CD 4 ( + ) CD 25 ( + ) regulatory T cells by TGF - beta induction of transcription factor Foxp 3
WJ Chen (2003)
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
S. Onizuka (1999)
10.1111/j.1749-6632.2009.04939.x
Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
Andrew J. Rech (2009)
10.1158/0008-5472.CAN-06-0261
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
T. Ishida (2006)
10.1182/blood-2008-12-195792
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
M. Ahmadzadeh (2009)
10.1158/0008-5472.CAN-04-3232
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
L. Ormandy (2005)
10.1159/000228433
British Society for Immunology
E. Langer (1957)
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J. Shimizu (1999)
10.1016/j.smim.2011.10.002
Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions.
T. Yamaguchi (2011)
10.4049/jimmunol.176.9.5136-a
Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”
S. Rosenberg (2006)
10.1038/nm1093
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
T. Curiel (2004)
Plasticity of Foxp 3 ( + ) T cells reflects promiscuous Foxp 3 expression in conventional T cells but not reprogramming of regulatory T cells
T Miyao (2012)
Induction of tumor immunity
J Shimizu (2011)
10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens
Denise Golgher (2002)
CD 25 ( + ) regulatory T cell depletion augments immunotherapy of micrometastases by an IL - 21 - secreting cellular vaccine
A Comes (2006)
10.1111/j.1442-2050.2009.01029.x
CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma.
T. Maruyama (2010)
10.4049/jimmunol.178.4.2155
Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance1
G. Zhou (2007)
predicts reduced survival
M Gobert (2004)
10.1172/JCI31911
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
M. Sharma (2007)
CD25(+) T regulatory cells: role of tumor-derived TGF-beta
(2007)
10.1038/sj.bjc.6605198
A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas
T. Schreiber (2009)
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
F. Thistlethwaite (2008)
10.1126/science.1203486
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
R. Schreiber (2011)
10.4049/jimmunol.178.5.2883
Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β
V. Liu (2007)
10.1007/s00262-007-0318-z
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
R. Griffiths (2007)
Nature of immunosuppressor
MI Greene (2006)
10.1200/JCO.2006.05.9584
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
G. Bates (2006)
10.1002/cncr.22282
Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients
R. Petersen (2006)
10.1038/sj.bjc.6605040
T-regulatory cell modulation: the future of cancer immunotherapy?
S. Nizar (2009)
Tumour-infiltrating T-cell
K Nosho (2009)
Unique chemotactic response
A Iellem (2006)
10.1182/BLOOD-2006-07-036863
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells.
A. Curti (2007)
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
D. Berd (1988)
10.1007/s00262-011-1046-y
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer
S. Ladoire (2011)
10.1172/JCI27745
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
S. Quezada (2006)
Disruption of CCR5
MCB Tan (2011)
10.1016/j.cell.2011.02.013
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
10.1038/ni904
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
J. Fontenot (2003)
10.4049/jimmunol.176.9.5136
Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”
D. O'Mahony (2006)
10.1038/nature06309
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel (2007)
10.1002/path.2774
Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
K. Nosho (2010)
10.1038/SJ.JID.5700122
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
R. Talpur (2006)
Prognostic value of tumor - infiltrating CD 4 ( + ) T - cell subpopulations in head and neck cancers
C Badoual (2006)
Specific recruitment
TJ Curiel (2010)
CCL 17 and CCL 22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma
T Maruyama (2010)
pathologic stage INSCLC patients
Q Gao (2006)
10.1007/s00262-006-0225-8
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
F. Ghiringhelli (2006)
Disruption of CCR 5 - dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer
Tan MCB (2009)
tumors to be curative
D Berd (2004)
10.4049/jimmunol.175.11.7746
Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade
A. Maker (2005)
10.1016/j.clim.2008.07.013
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.
L. Zhang (2008)
10.1084/JEM.194.6.847
Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells
A. Iellem (2001)
10.1073/PNAS.0509484103
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
M. Gavin (2006)
Intratumoural FOXP 3 - positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
G Perrone (2008)
10.1182/BLOOD-2005-06-2399
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
M. Ahmadzadeh (2006)
10.1136/gutjnl-2011-300970
Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer
G. Betts (2011)
10.1172/JCI25947
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
J. Dannull (2005)
10.4049/jimmunol.174.1.90
Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells1
S. Prasad (2005)
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
A. Hurwitz (2000)
10.1038/sj.gene.6364026
Cloning and characterization of GITR ligand
J. Kim (2003)
10.1016/j.immuni.2011.12.012
Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.
Takahisa Miyao (2012)
Different subsets of tumor infiltrat
YL Zhang (2006)
CD 8 + T cell immunity against a tumor / self - antigen is augmented by CD 4 ( + ) T helper cells and hindered by naturally occurring T regulatory cells
PA Antony (2005)
10.1016/J.CURRPROBLCANCER.2006.04.001
Hodgkin's lymphoma.
R. Tsang (2006)
10.1093/carcin/bgp127
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
F. Colotta (2009)
T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities.
R. Kurt (1995)
10.3324/haematol.11702
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma
A. Tzankov (2008)
10.1097/01.cji.0000175468.19742.10
Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma
P. Attia (2005)
A role for the transcription factor Helios in human CD 4 ( + ) CD 25 ( + ) regulatory T cells
D Getnet (2010)
Expression of helios
AM Thornton (2010)
Brain cancer immunoedit
S Pellegatta (2009)
10.1200/JCO.2008.18.7229
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
P. Salama (2009)
10.1038/nature03954
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
G. Willimsky (2005)
10.1038/nature10169
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
A. Facciabene (2011)
10.1097/CJI.0b013e3180600ff9
Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting Chemotherapy
D. Powell (2007)
10.1158/1078-0432.CCR-05-1886
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
C. Badoual (2006)
10.4049/jimmunol.164.5.2619
Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo1
S. Radoja (2000)
10.1158/1078-0432.CCR-07-4554
Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?
E. Jordanova (2008)
Modulation of tryptophan
A Curti (2007)
Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts.
S. Fujimoto (1976)
10.1186/1476-4598-9-4
Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways
Y. Zhang (2009)
FoxP3 transcription factor
T Miyao (2009)
10.1016/j.clim.2011.04.014
Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs.
E. Elkord (2011)
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
S. Sakaguchi (1995)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1038/ni1102-991
Cancer immunoediting: from immunosurveillance to tumor escape
Gavin P Dunn (2002)
10.1084/JEM.200509402092C
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K. Ko (2005)
10.4049/jimmunol.174.5.2591
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells
P. Antony (2005)
10.1038/mt.2010.34
Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.
Chi-An Chen (2010)
10.1158/0008-5472.CAN-05-4217
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.
B. Valzasina (2006)
CD 25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T - cell lymphoma
R Talpur (2006)
10.4049/jimmunol.176.3.1750
CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine1
A. Comes (2006)
10.1084/jem.20082205
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman (2009)
Intraepithelial CD8(+) tumor
E Sato (1996)
10.1093/INTIMM/12.5.639
TCR v(beta) usage and clonality of T cells isolated from progressing and rejected tumor sites before and after in vitro culture.
R. Kurt (2000)
10.1016/S0140-6736(03)12777-8
Hodgkin's lymphoma
L. Yung (2003)
10.4049/jimmunol.182.3.1746
Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer1
M. Tan (2009)
10.1084/jem.20050463
Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation
F. Ghiringhelli (2005)
10.1097/COC.0b013e318187dd40
A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
M. Gerena-Lewis (2009)
10.4049/jimmunol.179.7.4919
Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo1
D. Powell (2007)
10.1182/BLOOD-2004-06-2410
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
M. E. C. Lutsiak (2005)
10.1046/j.1440-1711.2002.01127.x
The role of CD4+CD25+ immunoregulatory T cells in the induction of autoimmune gastritis
K. Laurie (2002)
CTLA 4 blockade and GM - CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
MA Curran (2006)
CCL17 and CCL22 chemok
T Maruyama (2008)
Tumor evasion of the immune
VC Liu (2003)
10.1126/science.1129139
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
J. Galon (2006)
10.1111/j.1365-2249.2007.03521.x
Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
S. Audia (2007)
10.1016/J.JURO.2007.01.143
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
R. Lord (2007)
10.1158/1078-0432.CCR-06-0369
Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions
N. Hiraoka (2006)
10.1016/j.ejca.2008.05.017
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.
G. Perrone (2008)
10.1016/j.molimm.2010.02.001
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells.
D. Getnet (2010)
10.1002/eji.200324181
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F. Ghiringhelli (2004)
10.32388/i2tar4
The phase II trial.
R. Wittes (1985)
Nature of immunosuppressor T cells and their factors in tumor - bearing host ( Tbh )
MI Greene (1976)
Tumor infiltrating FOXP 3 ( + ) regulatory T - cells are associated with recurrence in pathologic stage INSCLC patients
RP Petersen (2006)
10.1038/ni759
Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance
J. Shimizu (2002)
10.1186/bcr787
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model
Y. Eralp (2004)
10.1158/0008-5472.CAN-06-0556
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins.
J. Bui (2006)
10.1073/PNAS.96.26.15074
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.
E. Kwon (1999)
10.1038/nri1806
Regulatory T cells, tumour immunity and immunotherapy
W. Zou (2006)
10.1084/JEM.194.6.823
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
R. P. Sutmuller (2001)
Functional delineation
M Miyara (2006)
T cells in vivo
YP Rubtsov (2009)
10.1002/ijc.23392
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer
Y. Mizukami (2008)
10.1158/1078-0432.CCR-08-1296
Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma
H. K. Jensen (2009)
A role for the transcrip
D Getnet (2011)
10.1126/science.1191996
Stability of the Regulatory T Cell Lineage in Vivo
Y. Rubtsov (2010)
10.1158/0008-5472.CAN-08-3289
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
M. Curran (2009)
10.1158/0008-5472.CAN-10-1797
Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.
J. Hindley (2011)
10.1158/0008-5472.CAN-08-2360
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.
Michael Gobert (2009)
10.1084/jem.20041130
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
M. Turk (2004)
Single-cell analysis of normal and FOXP 3-mutant human T cells : FOXP 3 expression without regulatory T cell development
M. Gavin (2006)
10.1186/bcr1586
Increased regulatory T-cell numbers distinguish high-risk breast cancer patients and those at risk of late relapse
G. Bates (2006)
Intraepithelial CD 8 ( + ) tumor - infiltrating lymphocytes and a high CD 8 ( + ) / regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato (2005)
10.1073/PNAS.0509182102
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
E. Sato (2005)
10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
C. Clemente (1996)



This paper is referenced by
10.1371/journal.pone.0107170
Inflammasome Activation Is Critical to the Protective Immune Response during Chemically Induced Squamous Cell Carcinoma
T. H. Gasparoto (2014)
10.1007/s11427-016-5024-7
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Fengtao You (2016)
10.1016/j.semcancer.2017.03.001
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation.
V. Huber (2017)
10.1093/carcin/bgy136
Breast cancer cell–derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells
Shengnan Hao (2018)
10.1038/cmi.2017.35
B cell regulation in cancer and anti-tumor immunity
Anushruti Sarvaria (2017)
Potential Immune Biomarkers in Gastrointestinal Cancers: Immune Inhibitory Molecules, Lymphocytes and Tumor Antigens
K. Sideras (2017)
10.4172/1948-5956.1000453
Assessment of cytokine mRNA expression profiles in tumor microenvironment and peripheral blood mononuclear cells of patients with high-grade serous carcinoma of the ovary
Pernilla Israelsson (2017)
10.3389/fimmu.2013.00190
Natural and Induced T Regulatory Cells in Cancer
Dennis O. Adeegbe (2013)
10.4103/UROS.UROS_11_19
Rational combination with an immunotherapy backbone in genitourinary cancers
Jhe-Cyuan Guo (2020)
10.1016/j.biopha.2018.03.063
Xihuang pill promotes apoptosis of Treg cells in the tumor microenvironment in 4T1 mouse breast cancer by upregulating MEKK1/SEK1/JNK1/AP-1 pathway.
L. Su (2018)
10.1155/2018/7946021
Secretory High-Mobility Group Box 1 Protein Affects Regulatory T Cell Differentiation in Neuroblastoma Microenvironment In Vitro
Thitinee Vanichapol (2018)
10.3389/fneur.2019.00337
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort
E. D’Amico (2019)
10.7603/S40730-015-0013-1
Stem cell technology and engineering for cancer treatment
S. N. Truong (2015)
10.5114/HPC.2018.76553
Vascular related pathologies in cardiovascular disease and cancer
S. Ananthaseshan (2018)
10.1530/ERC-13-0187
Metastatic mechanisms in follicular cell-derived thyroid cancer.
J. Phay (2013)
10.1007/s12253-017-0270-y
Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma
O. Stasikowska-Kanicka (2017)
10.2217/fon-2019-0468
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
A. Mavratzas (2019)
10.1080/2162402X.2015.1049803
T cell receptor mimic antibodies for cancer therapy
Leonid Dubrovsky (2016)
10.1097/CJI.0000000000000262
Suppressive Characteristics of Umbilical Cord Blood–derived Regulatory T Cells After Ex Vivo Expansion on Autologous and Allogeneic T Effectors and Various Lymphoblastic Cells
Thitinee Vanichapol (2019)
The role of glycosylation in regulatory T-cell biology
Faria Ferreira Cabral (2016)
10.1097/PAP.0000000000000116
Cancer Vaccines: Past, Present, and Future
S. Mohammed (2016)
10.1007/s12094-019-02128-5
Differences of the immune cell landscape between normal and tumor tissue in human prostate
E. Zhang (2019)
10.1515/raon-2016-0028
Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma
M. Skerget (2016)
10.1186/s13027-018-0183-8
Cellular prognostic markers in hepatitis-related hepatocellular carcinoma
A. Petrizzo (2018)
10.2741/4487
Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation.
Y. Keisari (2017)
10.1101/814095
Implications of Immune-Mediated Metastatic Growth on Metastatic Dormancy, Blow-Up, Early Detection, and Treatment
Adam Rhodes (2019)
10.12659/MSM.896629
Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells
Antonia Pavlovic (2016)
10.1016/j.critrevonc.2015.10.002
Cancer specific risk in multiple sclerosis patients.
A. Kyritsis (2016)
10.1038/cmi.2014.122
IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis
Qingshan Li (2015)
The role of IKKα during diet-induced obesity and glucose intolerance in insulin sensitive tissues. The role of glycosylation during intestinal carcinogenesis
Jessica Heringer (2014)
10.1080/03009734.2018.1555195
Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival
J. Lundberg (2019)
10.2147/OTT.S61794
Antitumor activity of total flavonoids from Tetrastigma hemsleyanum Diels et Gilg is associated with the inhibition of regulatory T cells in mice
Zhengquan Feng (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar